.png){kind=icon}
.png){kind=icon}
Return
Sparfloxacin reveals a host–virus dual-target antiviral scaffold against respiratory syncytial virus
.png){kind=icon}
OA
AI
Y
S
Y
T
A
A
T
H
K
M
Y
Y
S
K
K
S
T
H
Y
A
T
W
S
T
K
S
N
DOI：10.1038/s42003-026-10744-5.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness across the lifespan, particularly in infants and older adults. Nonetheless, effective antiviral therapies remain limited. Here, we performed a clinically guided, medium-throughput screening of approved drugs used in pediatric populations and identified sparfloxacin (SPFX), a fluoroquinolone antibiotic, as a mechanistically informative antiviral scaffold. SPFX showed antiviral activity against genetically distinct RSV clinical isolates in vitro, and suppressed RSV infection in a mechanistic mouse model in vivo. Mechanistically, our findings support a host–virus dual-target framework in which SPFX suppresses RSV replication through activity consistent with modulation of viral RNA polymerase function together with a pro-viral HSP70-associated host pathway. Using primary human pediatric airway epithelial cells, we identified SPFX-responsive host factors and observed suppression of HSP70 expression independent of infection. Together, these findings establish SPFX as a mechanistically informative antiviral scaffold and support a host–virus dual-target framework for future RSV therapeutic development. Sparfloxacin inhibits respiratory syncytial virus through dual targeting of the viral RNA polymerase and the host HSP70 pathway, providing a promising antiviral scaffold for future RSV therapeutic development.
Journal
IF:
5.1
Papers:
1.0W
Citations:
3.2W
Organization
Cited Papers